热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
PE/Cyanine7 anti-mouse CD3ε Antibody
产品名称：
PE/Cyanine7 anti-mouse CD3ε Antibody
产品类别：
抗体
产品编号：
100319
产品应用：
100319
[价格]
规格 价格 库存
25µg ￥ 1056 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32, ?and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Huang Y, et al. 2015. Proc Natl Acad Sci U S A. 112:39. PubMed
  2. Caba?ero D, et al. 2020. Elife. 9:00. PubMed
  3. Tran NT, et al. 2019. Cell Rep. 28:3510. PubMed
  4. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  5. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  6. Aguilar EG, et al. 2021. Blood Adv. 5:4219. PubMed
  7. Oetjen LK et al. 2017. Cell. 171(1):217-228 . PubMed
  8. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  9. Tatsuguchi T, et al. 2022. Int Immunol. 34:277. PubMed
  10. Zhu H, et al. 2018. Elife. 7:. PubMed
  11. Buxadé M, et al. 2018. J Exp Med. 215:2901. PubMed
  12. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  13. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  14. Li ZX, et al. 2022. Arch Virol. :. PubMed
  15. Huai W, et al. 2019. J Exp Med. 216:772. PubMed
  16. Tan L, et al. 2019. Cell Rep. 27:3657. PubMed
  17. Schulthess J et al. 2019. Immunity. 50(2):432-445 . PubMed
  18. Gopinathan G, et al. 2022. Mol Cancer Ther. 21:1030. PubMed
  19. Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  20. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  21. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  22. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  23. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  24. Li Z, et al. 2022. Elife. 11:. PubMed
  25. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  26. Tuttle KD, et al. 2020. Cell Rep. 33:108407. PubMed
  27. Xiao Y, et al. 2021. Cancer Cell. 39(3):423-437.e7. PubMed
  28. Emg?rd J, et al. 2018. Immunity. 143:419. PubMed
  29. Alexander RK, et al. 2020. eLife. 9:e54090.. PubMed
  30. Chun E, et al. 2020. Immunity. 51(5):871-884.e6.. PubMed
  31. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  32. Westfall S, et al. 2020. Brain Behav Immun. . PubMed
  33. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  34. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  35. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  36. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  37. Synn CB, et al. 2022. Clin Transl Immunology. 11:e1364. PubMed
  38. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  39. Lu M, et al. 2021. J Virol. 95:e0059221. PubMed
  40. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  41. Tran NT, et al. 2020. STAR Protocols. 1(1):100028. PubMed
  42. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  43. Williams JW, et al. 2017. Circ Res. 121:662. PubMed
  44. Kubota S, et al. 2019. Nat Commun. 10:1653. PubMed
  45. Wu S, et al. 2022. BMC Immunol. 23:17. PubMed
  46. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  47. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  48. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  49. Li J, et al. 2013. Arch Immunol Ther Exp (Warsz). 61:237. PubMed
  50. Huang Y, et al. 2016. J Immunol. 196: 217 - 231. PubMed
  51. Uematsu T, et al. 2016. Sci Rep. 6:37815. PubMed
  52. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  53. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  54. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  55. Riva A, et al. 2017. PLoS One.. 10.1371/journal.pone.0181964. PubMed
  56. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  57. Maniati E, et al. 2020. Cell Rep. 30:525. PubMed
  58. Damgaard RB et al. 2016. Cell. 166(5):1215-1230 . PubMed
  59. Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed
  60. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  61. Takahashi T, et al. 2017. J Exp Med. 10.1084/jem.20160247. PubMed
  62. Halim TYF et al. 2018. Immunity. 48(6):1195-1207 . PubMed
  63. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  64. Ireland L, et al. 2020. Front Immunol. 11:297. PubMed
  65. Hong JP, et al. 2020. Cell Reports Medicine. 1(3):100035. PubMed
  66. Qi Q, et al. 2009. Blood. 114:564. PubMed
  67. Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed
  68. Fitzpatrick Z, et al. 2020. Nature. 587:472. PubMed
  69. Chen J, et al. 2014. Cell Res. 24:1050. PubMed
  70. Walker JA, et al. 2020. Immunity. 51(1):104-118. PubMed
  71. White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed
  72. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  73. Celorrio M, et al. 2022. Acta Neuropathol Commun. 10:10. PubMed
  74. Fite BZ, et al. 2021. Sci Rep. 11:927. PubMed
  75. Wang Y, et al. 2020. Immunity. 53(6):1168-1181.e7. PubMed
  76. Goc J, et al. 2021. Cell. :. PubMed
  77. Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed
  78. Ioanna E Galani et al. 2017. Immunity. 46(5):875-890 . PubMed
  79. Nabekura T, et al. 2020. Immunity. 96:52. PubMed
  80. Uematsu T, et al. 2015. Sci Rep. 5: 17577. PubMed
RRID
AB_312684 (BioLegend Cat. No. 100319) AB_312685 (BioLegend Cat. No. 100320)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线